In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rebiotix Inc.

www.rebiotix.com

Latest From Rebiotix Inc.

Pipeline Watch: Phase II Readouts For Pamrevlumab, Mavacamten and Lefitolimod

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Execs On The Move, July 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical

Expedited Review Pathways: Three More Breakthroughs, Third RMAT Awarded

US FDA's popular breakthrough therapy designation given to Proteon's vonapanitase for dialysis patients, Synthetic Biologics' ribaxamase to prevent C. difficile infection, and River Vision's teprotumumab for thyroid eye disease; Vericel's cell therapy for heart failure is designated a regenerative medicine advanced therapy.

Review Pathway Regulation

Ferring Looks For Early Microbiome Wins, But Willing To Do Heavy Lifting

Switzerland’s Ferring is diving deep into the microbiome, looking at a range of potential therapy platforms including bacteriophage and probiotics. Its CSO believes a microbiome-based therapeutic approach could benefit dermatological and women’s health conditions, as well as gastro-intestinal disorders.

Research and Development Strategies Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Rebiotix Inc.
  • Senior Management
  • Lee Jones, Pres. & CEO
    Ken Blount, PhD, Head, External Research
    Greg Fluet, CBO
  • Contact Info
  • Rebiotix Inc.
    2660 Patton Rd.
    Roseville, MN 55113
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register